Pharma Giants Pour Billions Into Early China Biotech as US Tightens Rules
Merck, Novo Nordisk, and Novartis are putting over $300 million upfront into early-stage Chinese biotech deals. They’re chasing untested science while Washington signals a crackdown that could change global biotech rules.